Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin

PHASE4CompletedINTERVENTIONAL
Enrollment

13,511

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
TrachomaLymphatic Filariases
Interventions
DRUG

Administration of Albendazole on Day 1

Participants will receive Albendazole 400mg on study day 1.

DRUG

Administration of Ivermectin on Day 1

Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.

DRUG

Administration of Azithromycin on Day 1

Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.

DRUG

Administration of Azithromycin on Day 15

Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.

Trial Locations (1)

Unknown

Community Recruitment across whole district, Community Recruitment Across Whole District

All Listed Sponsors
collaborator

Armauer Hansen Research Institute, Ethiopia

OTHER

collaborator

Federal Minstry of Health of Ethiopia

OTHER_GOV

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT03570814 - Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin | Biotech Hunter | Biotech Hunter